Evolent Health (EVH) Tops Q2 EPS by 7c, Offers Guidance

Evolent Health (NYSE: EVH) reported Q2 EPS of ($0.03), $0.07 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $238.6 million versus the consensus estimate of $241.03 million.

GUIDANCE:

Evolent Health sees Q3 2020 revenue of $258-272 million, versus the consensus of $242 million.

Evolent Health sees FY2020 revenue of $995-1035 million, versus the consensus of $977.9 million.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Nike names former Pfizer CFO David Denton as new finance chief
• Morgan Stanley upgrades CDW on stronger AI-driven server demand